Fannin Innovation Studio
Contents
Program
"All companies in the Fannin portfolio are medical technology companies in the Texas Medical Center. Fannin Innovation Studio invests in these companies and works with them to take their ideas to market. In exchange for equity, the leaders of Fannin help co-found and manage the companies, and provide companies with working space, networking resources, and investment money. One of the three members of the leadership team manages each portfolio company. Fannin helps its portfolio companies gain grant money, secure licensing, seek mentorship, and move into the next stage of development." [[1]]
"Fannin’s model is to incubate its portfolio companies and provide shared management, thereby taking those costs off of the books of young biotech companies."
[Xconomy on Fanin and Acelerox]
Portfolio
- Accelerox
- ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
- ACF Pharmaceuticals
- Apaxis Medical
- Brevitest Technologies
- Clearview App
- Guidabot
- NewHeart
- Procyrion
- VC funding
- Pulmotect
Leadership Team
- Leo Linbeck III: Chairman and Founder, CEO of Aquinas Companies, LLC
- Dr. Atul Varadhachary, MD, PhD: Managing Partner
- Mark Worscheh: CFO, Executive VP of Aquinas Companies, LLC
Contact
3900 Essex Lane, Suite 575 Houston, Texas 77027
